Your browser doesn't support javascript.
Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England.
Khunti, Kamlesh; Knighton, Peter; Zaccardi, Francesco; Bakhai, Chirag; Barron, Emma; Holman, Naomi; Kar, Partha; Meace, Claire; Sattar, Naveed; Sharp, Stephen; Wareham, Nicholas J; Weaver, Andy; Woch, Emilia; Young, Bob; Valabhji, Jonathan.
  • Khunti K; National Diabetes Audit Programme, NHS England & Improvement, London, UK; Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK. Electronic address: kk22@le.ac.uk.
  • Knighton P; National Diabetes Audit Programme, NHS England & Improvement, London, UK; NHS Digital, Leeds, UK.
  • Zaccardi F; Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK.
  • Bakhai C; NHS England and NHS Improvement, London, UK.
  • Barron E; NHS England and NHS Improvement, London, UK.
  • Holman N; National Diabetes Audit Programme, NHS England & Improvement, London, UK; NHS Digital, Leeds, UK; NHS England and NHS Improvement, London, UK; Institute of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, UK.
  • Kar P; National Diabetes Audit Programme, NHS England & Improvement, London, UK; NHS England and NHS Improvement, London, UK; Portsmouth Hospitals NHS Trust, Portsmouth, UK.
  • Meace C; National Diabetes Audit Programme, NHS England & Improvement, London, UK; NHS Digital, Leeds, UK.
  • Sattar N; National Diabetes Audit Programme, NHS England & Improvement, London, UK; Institute of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, UK.
  • Sharp S; MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
  • Wareham NJ; MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
  • Weaver A; NHS England and NHS Improvement, London, UK.
  • Woch E; National Diabetes Audit Programme, NHS England & Improvement, London, UK; NHS Digital, Leeds, UK.
  • Young B; National Diabetes Audit Programme, NHS England & Improvement, London, UK; Diabetes UK, London, UK.
  • Valabhji J; National Diabetes Audit Programme, NHS England & Improvement, London, UK; NHS England and NHS Improvement, London, UK; Department of Diabetes and Endocrinology, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK; Division of Metabolism, Digestion and Reproduction, Imperial Col
Lancet Diabetes Endocrinol ; 9(5): 293-303, 2021 05.
Article in English | MEDLINE | ID: covidwho-1531930
Semantic information from SemMedBD (by NLM)
1. Therapeutic procedure TREATS Diabetes Mellitu
Subject
Therapeutic procedure
Predicate
TREATS
Object
Diabetes Mellitu
2. Diabetes Mellitu PROCESS_OF C0027361
Subject
Diabetes Mellitu
Predicate
PROCESS_OF
Object
C0027361
3. Therapeutic procedure TREATS Persons
Subject
Therapeutic procedure
Predicate
TREATS
Object
Persons
4. Diabetes Mellitu PROCESS_OF C0030705
Subject
Diabetes Mellitu
Predicate
PROCESS_OF
Object
C0030705
5. glucose INHIBITS Pharmaceutical Preparations
Subject
glucose
Predicate
INHIBITS
Object
Pharmaceutical Preparations
6. Prescription procedure TREATS Diabetes Mellitu
Subject
Prescription procedure
Predicate
TREATS
Object
Diabetes Mellitu
7. Prescription procedure TREATS Persons
Subject
Prescription procedure
Predicate
TREATS
Object
Persons
8. COVID-19 PROCESS_OF Persons
Subject
COVID-19
Predicate
PROCESS_OF
Object
Persons
9. Therapeutic procedure TREATS Diabetes Mellitus, Non-Insulin-Dependent
Subject
Therapeutic procedure
Predicate
TREATS
Object
Diabetes Mellitus, Non-Insulin-Dependent
10. Diabetes Mellitus, Non-Insulin-Dependent PROCESS_OF Persons
Subject
Diabetes Mellitus, Non-Insulin-Dependent
Predicate
PROCESS_OF
Object
Persons
11. Therapeutic procedure TREATS Persons
Subject
Therapeutic procedure
Predicate
TREATS
Object
Persons
12. Diabetes Mellitus, Non-Insulin-Dependent PROCESS_OF Patients
Subject
Diabetes Mellitus, Non-Insulin-Dependent
Predicate
PROCESS_OF
Object
Patients
13. glucose INHIBITS Pharmaceutical Preparations
Subject
glucose
Predicate
INHIBITS
Object
Pharmaceutical Preparations
14. Prescription procedure TREATS Diabetes Mellitus, Non-Insulin-Dependent
Subject
Prescription procedure
Predicate
TREATS
Object
Diabetes Mellitus, Non-Insulin-Dependent
15. Prescription procedure TREATS Persons
Subject
Prescription procedure
Predicate
TREATS
Object
Persons
16. COVID-19 PROCESS_OF Persons
Subject
COVID-19
Predicate
PROCESS_OF
Object
Persons
ABSTRACT

BACKGROUND:

In patients with type 2 diabetes, hyperglycaemia is an independent risk factor for COVID-19-related mortality. Associations between pre-infection prescription for glucose-lowering drugs and COVID-19-related mortality in people with type 2 diabetes have been postulated but only investigated in small studies and limited to a few agents. We investigated whether there are associations between prescription of different classes of glucose-lowering drugs and risk of COVID-19-related mortality in people with type 2 diabetes.

METHODS:

This was a nationwide observational cohort study done with data from the National Diabetes Audit for people with type 2 diabetes and registered with a general practice in England since 2003. Cox regression was used to estimate the hazard ratio (HR) of COVID-19-related mortality in people prescribed each class of glucose-lowering drug, with covariate adjustment with a propensity score to address confounding by demographic, socioeconomic, and clinical factors.

FINDINGS:

Among the 2 851 465 people with type 2 diabetes included in our analyses, 13 479 (0·5%) COVID-19-related deaths occurred during the study period (Feb 16 to Aug 31, 2020), corresponding to a rate of 8·9 per 1000 person-years (95% CI 8·7-9·0). The adjusted HR associated with recorded versus no recorded prescription was 0·77 (95% CI 0·73-0·81) for metformin and 1·42 (1·35-1·49) for insulin. Adjusted HRs for prescription of other individual classes of glucose-lowering treatment were as follows 0·75 (0·48-1·17) for meglitinides, 0·82 (0·74-0·91) for SGLT2 inhibitors, 0·94 (0·82-1·07) for thiazolidinediones, 0·94 (0·89-0·99) for sulfonylureas, 0·94 (0·83-1·07) for GLP-1 receptor agonists, 1·07 (1·01-1·13) for DPP-4 inhibitors, and 1·26 (0·76-2·09) for α-glucosidase inhibitors.

INTERPRETATION:

Our results provide evidence of associations between prescription of some glucose-lowering drugs and COVID-19-related mortality, although the differences in risk are small and these findings are likely to be due to confounding by indication, in view of the use of different drug classes at different stages of type 2 diabetes disease progression. In the context of the COVID-19 pandemic, there is no clear indication to change prescribing of glucose-lowering drugs in people with type 2 diabetes.

FUNDING:

None.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Diabetes Mellitus, Type 2 / COVID-19 / Hypoglycemic Agents Subject: Diabetes Mellitus, Type 2 / COVID-19 / Hypoglycemic Agents Type of study: Etiology study / Incidence study / Observational study / Prognostic study / Risk factors Language: English Journal: Lancet Diabetes Endocrinol Clinical aspect: Etiology Year: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Diabetes Mellitus, Type 2 / COVID-19 / Hypoglycemic Agents Subject: Diabetes Mellitus, Type 2 / COVID-19 / Hypoglycemic Agents Type of study: Etiology study / Incidence study / Observational study / Prognostic study / Risk factors Language: English Journal: Lancet Diabetes Endocrinol Clinical aspect: Etiology Year: 2021
...